According to a new market report published by Lucintel, the future of the liquid biopsy market looks promising with opportunities in the reference laboratories, hospitals, physician laboratories, and academic and research centers end use segments. The liquid biopsy market is expected to grow with a CAGR of 23% from 2019 to 2024. The major drivers for this market are increasing prevalence of cancer, increasing preference for noninvasive procedures, rising emphasis on personalized medicine, and availability of funding for liquid biopsy research and development.
Liquid biopsy tests are executed to understand the molecular aspects of early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring orthopedics applications. Therapy selection is the largest application segment of the liquid biopsy market.
North America will remain the largest region over the forecast period due to recent regulatory approvals by CE for commercial use of these liquid biopsy tests.
Biocept, Qiagen N.V., Roche Diagnostics, Bio-Rad Laboratories, Myriad Genetics, Menarini-Silicon Biosystems, Trovagene, Guardant Health, Mdxhealth, Genomic Health, Raindance Technologies, Thermo Fisher Scientific, and Illumina are among the major players of liquid biopsy.
Lucintel, a leading global strategic consulting and market research firm, has analyzed growth opportunities in the liquid biopsy market by product, circulating biomarker, clinical application, application, end use, and region. Lucintel has prepared a comprehensive research report titled " Liquid Biopsy Market 2019-2024: Trends, Forecast, and Opportunity Analysis". The Lucintel report serves as a catalyst for growth strategy as it provides comprehensive data and analysis on trends, key drivers, and directions. The study includes a forecast for the liquid biopsy market by product, circulating biomarker, clinical application, application, end use, and region as follows:
By Product [$M shipment analysis for 2013 – 2024]:
• Assays Kits
• Instruments
• Services
By Circulating Biomarker [$M shipment analysis for 2013 – 2024]:
• Circulating Tumor Cells (CTCs)
• Circulating Tumor DNA (ctDNA)
• Cell-Free DNA (cfDNA)
• Extracellular Vesicles (EVs)
• Other Circulating Biomarkers
By Clinical Application [$M shipment analysis for 2013 – 2024]:
• Early Cancer Screening
• Therapy Selection
• Treatment Monitoring
• Recurrence Monitoring Orthopedics
By Application [$M shipment analysis for 2013 – 2024]:
• Oncology
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Liver Cancer
• Other Cancers
• Non-Cancer
By End Use [$M shipment analysis for 2013 – 2024]:
• Reference Laboratories
• Hospitals and Physician Laboratories
• Academic and Research Centers
• Other End Users
By Region [$M shipment analysis for 2013 – 2024]:
• North America
o United States
o Canada
o Mexico
• Europe
o United Kingdom
o Germany
o France
o Italy
o Spain
• Asia-Pacific
o China
o India
o Japan
• ROW
o Brazil
A report of more than 150 pages will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link…… or [email protected].
About Lucintel
Lucintel, the premier global management consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, growth consulting, M&A, and due diligence services to executives and key decision-makers in a variety of industries. For further information, visit www.lucintel.com.
This report addresses the following key questions:
Q.1. What are some of the most promising potential, high-growth opportunities for the liquid biopsy market by product (assays kits, instruments, and services), circulating biomarker (circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers (include circulating RNA (ctRNA and cfRNA) and cell-free protein biomarkers), clinical application (early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring orthopedics), application (oncology, lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer, other cancers (bladder cancer, pancreatic cancer, brain and nervous system cancer, ovarian cancer and melanoma), non-cancer application), end use (reference laboratories, hospitals and physician laboratories, academic and research centers, and other end users), and region (North America, Europe, Asia-Pacific, and ROW)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which regions will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the drivers and challenges of the liquid biopsy market?
Q.5. What are the business risks and threats to the liquid biopsy market?
Q.6. What are emerging trends in this liquid biopsy market and the reasons behind them?
Q.7. What are some changing demands of customers in the liquid biopsy market?
Q.8. What are the new developments in the liquid biopsy market? Which companies are leading these developments?
Q.9. Who are the major players in this liquid biopsy market? What strategic initiatives are being implemented by key players for business growth?
Q.10. What are some of the competitive products and processes in this liquid biopsy area and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11. What M & A activities have taken place in the last 5 years in liquid biopsy market?